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III. Abbreviations 
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ATCC American Type Culture Collection 
BSA Bovine serum albumin 
BCA Bicinchoninic acid 
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M-MuLV Moloney murine leukemia virus 
NaCl Sodium chloride 
nM nanomolar 
p21 protein 21 
p53 protein 53 
PBS Phosphate buffer saline 
PCR Polymerase chain reaction 
pmol picomole 
RT-PCR Reverse transcription-PCR 
RNA Ribonucleic acid 
Rnase Ribonuclease 
RPMI Roswell park memorial institute 
RT Room temperature 
si-RNA Small interfering RNA 
s Second 
TCC transitional cell carcinoma 
Tris Tris-(hydroxy methyl)-amino methane 
TBST Tris-Buffered Saline and Tween 20 
V Volt 
V/V Volume to volume 
XTT 2,3-Bis(2-methoxy-4-nitro-5-ulfophenyl)-2H-tetrazolium-5- 
 carbox-anilide 
μl microlitre 
μM micromolar 
μm micrometer 
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1.Introduction 
 
1.1 Phylogeny of melanoma-associated antigen (MAGE) family 
 
In 1991, the first melanoma-associated antigen gene was identified by Terry Boon and 
his colleagues (Simpson et al., 2005; Traversari et al., 1992b; van der Bruggen et al., 
1991) in a melanoma patient. The identification of this MAGE gene was due to its 
processing and expression as a peptide bound to major histocompatibility complexes 
on the cell surface (Herin et al., 1987; Traversari et al., 1992a; van der Bruggen et al., 
1991). This gene was later renamed MAGE-A1 because it was found to belong to a 
12-hMAGE-A genes cluster (Chomez et al., 2001). The family of MAGE genes has 
undergone expansion during the past years and now consists of approximately 60 
identified members that are still under experimental investigation (Chomez et al., 
2001). The functional role of most MAGE family members remains to be 
characterized. Recent studies are beginning to provide insights into MAGE gene 
functions and their potential for cancer immunotherapy. 
 
1.2 Classification of MAGE family 
 
Based on their different expression patterns, chromosomal locations, and gene 
structures, the MAGE family has been divided into two subfamilies: type I 
cancer-testis antigens (CTA) and type II omnipresent MAGEs. 
 
Type I MAGE genes are located in clusters of the X chromosome and rarely 
expressed in normal adult tissues except testis, trophoblast, and placenta (Barker and 
Salehi, 2002; Simpson et al., 2005), but have high expressions in various cancers. 
These genes have been classified as type I MAGE genes which belong to CTA due to 
their special expression pattern, genomic clustering, and single exon open reading 
frame. Type I MAGE genes consist of MAGE-A, -B, and -C groups according to 
chromosomal localization (Lucas et al., 1998; Muscatelli et al., 1995; Rogner et al., 
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1995). MAGE-A, -B, and -C genes locate in the q28, p21-22 and q26-27 regions of 
the X chromosome, respectively (Dabovic et al., 1995; De Plaen et al., 1994; Lucas et 
al., 2000; Lucas et al., 1998; Lurquin et al., 1997; Muscatelli et al., 1995; Rogner et 
al., 1995) (Figure 1). 
 
 
Figure 1: Chromosomal locations of the human MAGE genes  
*Figure modified from Sang et al.(Sang et al., 2011b). 
 
Type II MAGE gene family consist of 15 genes and their genomic locations are not 
limited to the X chromosome. They are broadly expressed in a variety of normal adult 
tissues (Ohman Forslund and Nordqvist, 2001) and not specifically related to cancer 
(De Plaen et al., 1999; Osterlund et al., 2000; Sang et al., 2011b). Furthermore, type 
II MAGE genes are related to many biologic processes, such as cell cycle withdrawal, 
neuronal differentiation and programmed cell death (Barker and Salehi, 2002; 
Espantman and O'Shea, 2010). 
 
1.3 Structure of MAGE 
 
MAGE genes belong to a large gene family and all members have a conserved 
165-171 amino acid domain in the center of the molecule (Figure 2) named MAGE 
homology domain (MHD) (Chomez et al., 2001; Lopez-Sanchez et al., 2007). 
 
Human MHDs consist of 165-171 amino acids and can be divided into five different 
regions which represent distinct areas of conservation (Barker and Salehi, 2002). It 
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has been shown that the MHD contains at least four potential α-helical domains and 
five regions of α-sheet structure according to the structural predictions. Additionally, 
a single MHD flanked by a small amount of poorly conserved N- and C-terminal 
sequence exists in most of type I MAGE genes. Type II MAGE family members can 
be divided into two groups: one group includes Necdin, MAGE-F1, and MAGE-G1 
whose structures are similar to MAGE-A and -B genes; the other group are larger 
proteins with extended N- or C-termini including MAGE-D1-4, MAGE-E1, and 
MAGE-L2 (Figure 2B). 
 
 
Figure 2: The phylogeny and structure of MAGE family members  
A: An evolutionary tree using the aligned MHDs shows the relationship of MAGE family 
members. B: Domain structures of selected MAGE family members are shown. MHD: 
MAGE homology domain. MHD2: a loosely conserved region located in the N-terminal 
domain of some type II MAGE genes. The presence of truncated MHDs was indicated by the 
notched lines in the MHDs of MAGE-E1 and MAGE-H1. 
*Figure modified from Barker PA et al.(Barker and Salehi, 2002). 
A 
B 
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1.4 Expression of MAGE 
 
It has been described previously that type I MAGE genes are normally restricted in 
their expression to the testis, trophoblast, and placenta. It also has been shown that 
aberrant type I MAGE expressions could be detected in various human cancers, 
including melanoma, lung cancer, breast cancer, oral squamous cell carcinoma, 
esophageal carcinoma, urothelial malignancies, hematopoietic malignancies, etc. 
(Bergeron et al., 2009; Brasseur et al., 1995; Jang et al., 2001; Lin et al., 2004; Otte et 
al., 2001; Ries et al., 2009; Suyama et al., 2002). 
 
Among various cancers, melanoma and lung cancer have the highest frequency of 
type I MAGE gene expression. It was reported that the frequencies of MAGE-A1, A3 
and C1 gene expression in melanoma specimens were 36%, 69% and 46%, 
respectively (Gaugler et al., 1994; Itoh et al., 1996; Lucas et al., 1998). MAGE-A3 
gene was expressed in 76% of metastatic melanoma cases (Ohman Forslund and 
Nordqvist, 2001). It was also shown that MAGE-B1 and B2 gene had very high 
expression in lung cancer and melanoma (De Smet et al., 1999). The frequency of 
MAGE-I mRNA expression was found to be intermediate in other epithelial cancers, 
such as breast cancer, prostate cancer and bladder cancer. But the frequency of 
MAGE-I mRNA expression is extremely low in renal cancer, colon cancer, pancreatic 
cancer and hematopoietic malignancies including lymphomas and leukemia. 
 
At present, most studies demonstrated that the expression of type I MAGE gene was 
closely related to the staging, metastasis and recurrence of malignant tumors (Kufer et 
al., 2002; Mou et al., 2002; Taback et al., 2001). However, there are still a lot of 
disputations on the relationship between type I MAGE gene expression and the 
occurrence and development of malignant tumors. 
 
Type II MAGE genes differ greatly from type I MAGE genes in expression. Type II 
MAGE genes are not limited to germline expression and can be broadly expressed in 
a variety of normal adult tissues. Only several type II MAGE genes, such as necdin 
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and MGAE-E1, are highly expressed in various forms of cancer (Masuda et al., 2001; 
Muscatelli et al., 2000; Niinobe et al., 2000; Ohman Forslund and Nordqvist, 2001; 
Salehi et al., 2000; Sasaki et al., 2001). 
 
1.5 Function of MAGE 
 
Although MAGE genes were identified twenty years ago, their possible biological 
functions on cellular transformation or tumor progression are largely unknown. But 
studies from diverse areas now suggested that they might be involved in the 
regulation of cell survival, cell cycle progression, and cell apoptosis. 
 
Some evidences have been reported that MAGE-A antigens may have some important 
effects in human tumors. Overexpression of MAGE-A11 was found to promote 
transcriptional activity of androgen receptor (AR) and thus promote the progression of 
prostate cancer (Askew et al., 2010; Askew et al., 2009; Bai et al., 2005; Bai and 
Wilson, 2008). Additionally, Overexpression of MAGE-A11 markedly promoted 
breast cancer cell proliferation and the capacity of producing colonies (Xia et al., 
2012). Down-regulation of MAGE-A3 was shown to induce apoptosis or reduce cell 
survival in various cell lines through different mechanism (Nardiello et al., 2011; 
Yang et al., 2007; Zhu et al., 2008). MAGE-A1 was found to function as a 
transcriptional inhibitor by binding to Ski interacting protein and by recruiting histone 
deacetylase 1 (Laduron et al., 2004). Furthermore, some MAGE-A proteins including 
MAGE-A1, -A2, -A3, and -A6 are able to suppress p53 transactivation function 
which result in the resistance to anti-tumor drugs (Monte et al., 2006). Recently, it 
was identified that some MAGE proteins such as a sub-family E3 ubiquitin ligases 
were able to interact with RING domain proteins, thus promoting the ubiquitylation 
and the subsequent p53 degradation (Doyle et al., 2010; Espantman and O'Shea, 2010; 
Feng et al., 2011; Zendman et al., 2003). These data suggest that MAGE-A proteins 
may function as oncoproteins inhibiting cell apoptosis and promoting cell 
proliferation so that they facilitate the development of malignancies. 
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However, MAGE-A4 is a untypical member among the MAGE-A family. A 
retrospective study showed that patients with MAGE-A4 expression survived 
significantly longer than MAGE-A4-negative patients (Bandic et al., 2006). 
MAGE-A4 was found to induce apoptosis when it was overexpressed in human cells 
(Peikert et al., 2006; Sakurai et al., 2004). Furthermore, it was shown that MAGE-A4 
could bind to Gankyrin which has been implicated in the formation of hepatocellular 
carcinoma and inhibited Gankyrin-mediated carcinogenesis (Nagao et al., 2003). 
Therefore, MAGE-A4 was considered as an anti-oncogenic protein in malignancies. 
 
Some MAGE II proteins such as Necdin, MAGE-D1 and MAGE-D4 have been 
involved in cell proliferation and apoptosis according to recent studies. Necdin was 
found to interact with E2F1 and p53 thus inhibiting cell growth and apoptosis 
(Taniura et al., 1999; Taniura et al., 1998). MAGE-D1 was found to inhibit cell cycle 
progression and induce apoptosis which depends on nerve growth factor through 
interacting with p75 neurotrophin receptor and inhibitor of apoptosis proteins (IAP) 
(Jordan et al., 2001; Salehi et al., 2000). Moreover, overexpression of MAGE-D4B 
exhibited an increase of cell growth and promoted migration in oral squamous cancer 
(Chong et al., 2012). 
 
In sum, the known biological functions of MAGEs in different cells can be quite 
heterogenous. 
 
1.6 Type I MAGE antigens and tumor specific immune therapy 
 
For developing antigen-specific cancer immunotherapy, the most crucial step is to 
discover rational target antigens which must have no or highly restricted expression in 
normal tissues so that the autoimmunity can be avoided. Type I MAGE antigens have 
gained extensive attention on the development of effective anticancer 
immunotherapies in recent years due to their tumor-specific expression. It has to be 
mentioned that testis which expresses MAGE-I is regarded as an immunoprivileged 
organ and can escape from autoimmune response. 
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Type I MAGE antigens are the best studied CTA, particularly the MAGE-A 
subcategory. MAGE-A antigens are one of the most appropriate target antigens for 
immunotherapy because they are strictly tumor specific and are expressed in a large 
variety of tumors. Graff-Dubois’s study showed that several heteroclitic peptides such 
as p248V9, p248G9 and p248D9, derived from MAGE-A1, -A2, -A3, -A4, -A6, -A10 
and MAGE-A12, were able to stimulate cytotoxic T lymphocytes which could 
recognize each MAGE-A antigen individually and lead to tumor cells destruction 
(Graff-Dubois et al., 2002). 
 
Dozens of clinical studies of therapeutic vaccination targeting these antigens have 
been performed, particularly MAGE-A3. There are two large phase III clinical trials 
which have been initiated in patients with melanoma skin cancer and non-small cell 
lung cancer, using MAGE-A3 as an adjuvant immunotherapy (Russo et al., 2011; 
Tyagi and Mirakhur, 2009). The studies will also evaluate potential side effects of 
MAGE-A3 ASCIs (Antigen-specific cancer immuno-therapeutics). 
 
1.7 Tumor specific immune therapy for bladder cancer 
 
Bladder cancer is a worldwide health problem with an age-standardised incidence rate 
(per 100000 persons) of 17.7 for males and 3.5 for females in Europe. 95% of bladder 
cancers are defined as transitional cell carcinoma (TCC) (Patton et al., 2002), and 
75% of them are superficial (Amling, 2001). Most TCCs are likely to recur after 
treatment and a significant proportion (5%–25%) of the recurrences will progress to a 
more aggressive stage. It has been shown that superficial bladder cancer effectively 
responds to nonspecific immunotherapy with Bacillus Calmette-Guerin (BCG) by 
using intravesical treatment, especially carcinoma in situ disease. This treatment is 
partially succesful to prevent recurrence and progression of bladder cancer after 
surgery (Nseyo and Lamm, 1997). Based on this finding, development of 
immunotherapeutic approaches targeting MAGE are suggested for treatment of 
bladder cancer. Therefore, MAGEs are under investigation as possible targets for 
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bladder cancer immunotherapy. In particular, MAGE-A3 is one of the most 
abundantly expressed MAGE subtype in bladder cancer (Yin et al., 2011) and 
MAGE-A3 vaccination protocols are investigated in clinical trials. Interestingly, a 
recent study with recombinant MAGE-A3 combined with local BCG 
immunostimulation for treatment of non-muscle-invasive bladder cancer increased 
total and vaccine-specific T-cells in the bladder (Derre et al., 2017). However, so far, 
the intrinsic functions of MAGE-A3 in bladder cancer cells are not clear and represent 
the topic of this study. 
 
Aims of the study  
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2. Aims of the study 
 
The type I Melanoma Antigen Genes such as MAGE-A3 are expressed in various 
cancers including bladder cancer. In normal tissues, MAGE-A3 is restricted to testis 
and placenta representing tissues with low antigen presentation. Thus, MAGE-A3 
represents a candidate antigen as possible target for cancer immunotherapy. In 
particular, MAGE-A3 vaccination protocols are investigated in clinical trials in 
bladder cancer. So far, the intrinsic functions of MAGE-A3 in bladder cancer cells are 
not clear. Different MAGE-A types have been demonstrated to favour or to impede 
oncogenicity in other cancer types. 
 
This study aimed to analyze whether MAGE-A3 affects oncogenicity in bladder 
cancer cells. To follow this aim we performed the following strategy: 
 
1. MAGE-A3 expression analysis in bladder cancer cell lines and selection of cell 
lines for further functional analysis of MAGE-A3. 
2. Establishment of silencing of MAGE-A3 by RNA interference with synthetic 
siRNA. 
3. Functional analyses of MAGE-A3 with respect to proliferation, cell viability and 
apoptosis in bladder cancer cell lines employing silencing of MAGE-A3. 
4. Proteomic array analysis of components relevant for proliferation and apoptosis 
after silencing of MAGE-A3. 
Materials and methods  
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3. Materials and methods 
 
3.1 Materials 
 
3.1.1 Cells  
Human bladder carcinoma cell lines used in the experiment were purchased from 
Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures 
(DSMZ) (T24, 5637, HT-1376 and BFTC-905), American type culture collection 
(ATCC) (UMUC-3), or Cell Line Service (CLS) (EJ-28). 
 
3.1.2 Oligonucleotides for quantitative RT-PCR 
 
The oligonucleotides were synthesized by Biomers (Biomers, Ulm, Germany) 
 
β-ACTIN 
Forward    5′-TATCCAGGCTGTGCTATCCCTGTAC-3′ 
Reverse    5′-TTCATGAGGTAGTCAGTCAGGTCCC-3′ 
 
MAGE-A3 
Forward  5′-GAGTCATCATGCCTCTTGAGCAGAG-3′ 
Reverse  5′-GAGGGTAGTTCATGGTAGTGGGGAG-3′ 
 
3.1.3 Small interfering RNA sequences  
 
The oligonucleotides were synthesized by Biomers (Biomers, Ulm, Germany) 
 
Si-MAGE-A3 
Forward  5′-GGUAAAGAUCAGUGGAGGA dTdT-3′ 
Reverse  5′-UCCUCCACUGAUCUUUACC dTdT-3′ 
 
Si-Random 
Forward  5′- UAGCGACUAAACACAUCAA dTdT -3′ 
Reverse  5′- UUGAUGUGUUUAGUCGCUA dTdT -3′ 
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3.1.4 Enzymes 
 
DNase I 
DNase I (RNase-free) was purchased from Fermentas (Fermentas GmbH, St. 
Leon-Rot, Germany). DNase I is an endonuclease that nonspecifically cleaves DNA 
to release di-, tri- and oligonucleotide products with 5′-phosphorylated and 
3′-hydroxylated ends. DNase I acts on single- and double-stranded DNA, chromatin 
and RNA: DNA hybrids. It is frequently used to remove contaminating genomic DNA 
from RNA samples. (* modified from the product information of Thermo Fisher 
Scientific Inc.) 
 
RevertAidTM Reverse Transcriptase 
RevertAidTM Reverse Transcriptase was purchased from Fermentas (Fermentas 
GmbH, St. Leon-Rot, Germany). It is a genetically modified M-MuLV RT and differs 
from wildtype M-MuLV RT by its structure, catalytic properties and in the optimum 
activity temperature. The enzyme possesses RNA-dependent and DNA-dependent 
polymerase activity and a RNase H activity specific to RNA in RNA-DNA hybrids. 
RevertAid™ Reverse Transcriptase activity is optimal at 42°C (active up to 50°C). 
The enzyme is capable of first strand cDNA synthesis up to 13 kb. The enzyme 
incorporates modified nucleotides. (* modified from the product information of 
Thermo Fisher Scientific Inc.) 
 
RiboLock RNase Inhibitor  
RiboLock RNase inhibitor was purchased from Fermentas (Fermentas GmbH, St. 
Leon-Rot, Germany). It inhibits the activity of RNases by binding them in a 
noncompetitive mode at a 1:1 ratio. It does not inhibit eukaryotic Rnases: T1, T2, U1, 
U2, CL3, as well as prokaryotic RNases I and H. Its source is E.coli cells with a 
cloned gene encoding mammalian ribonuclease inhibitor with molecular weight of 
49.6 kDa monomer. (* modified from the product information of Thermo Fisher 
Scientific Inc.) 
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3.1.5 Antibodies 
 
Antibodies used in the experiments are all commercially available. Their parameters 
were described as follows: 
 
Primary antibodies                                         Company 
Anti-human MAGE-A3 (monoclonal) mouse                  Proteintech /USA 
 
Link antibody 
Biotinylated rabbit anti-mouse immunoglobulins        Dako, Hamburg, Germany 
 
3.2 Methods 
 
3.2.1 Cell culture of T24, UMUC-3, EJ-28 cells 
 
The cell culture was performed according to the protocols provided by DSMZ, ATCC 
and CLS. The cells frozen in 10% DMSO in liquid nitrogen (approx. 5 x 106 cells/ml) 
were thawed rapidly at 37°C and then added drop wise to 100 mm dish containing 
10ml of pre-warmed RPMI1640 medium (supplemented with 10% (v/v) FCS (fetal 
calf serum, heat inactivated for 30 min at 56 °C), sterile filtered, 1% (v/v) penicillin 
and streptomycin, and 1% (v/v) L-glutamine (medium and all supplements were from 
PAA Laboratories GmbH, Pasching, Austria)). When the cells became confluent, they 
were trypsinized with 2 ml 1 x trypsin per 100 mm plate for approximate 5 min at 
37°C. The reaction was stopped by adding 5 ml of medium with 10% FCS containing 
trypsin inhibitors. For continuous culture, about 1/4 of the medium containing the 
cells were transferred to a fresh plate and cultured in a gas controlled incubator (Hera 
cell, kendro Laboratory Products GmbH, Langenselbold, Germany) with 
water-saturated atmospheric air and 5% CO2. 
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1 x Trypsin Volume 
10 x Trypsin 10 ml 
HEPES (200 mM) 10 ml 
Isotonic NaCl (0.9%) 80 ml 
 
3.2.2 Small interfering RNA preparation and transfection 
 
Selective inhibition of target gene was performed using specific si-RNAs. As a 
control, si-Random sequence was employed that does not target any gene in the 
human genome and has been tested by micro-array analysis (Dharmacon Inc., 
Chicago, IL, USA). The forward and reverse RNA strands with two 5′ 
deoxy-thymidine overhangs were commercially synthesized and annealed at a final 
concentration of 20 µM at 37°C for 1h in annealing buffer. The principle of this 
siRNA technique has been described (Pei and Tuschl, 2006). 
 
 
The INTERFERinTM (Polyplus-Transfection, NewYork, USA) mediated transfection 
method was employed for transfection of T24, UMUC-3 and EJ-28 cells. 
INTERFERinTM is a powerful siRNA transfection reagent that ensures efficient gene 
silencing and reproducible transfection. INTERFERinTM delivers efficiently siRNA 
duplexes to mammalian cells. One day before transfection, appropriate numbers of 
T24, UMUC-3 and EJ-28 cells were plated on respective culture dishes with growth 
medium, so that they will become 30-50% confluent at the time of transfection. 
RNA duplex annealing buffer Final concentration 
potassium acetate 20 mM 
HEPES-KOH 6 mM 
magnesium acetate 0.4 mM 
pH 7.4 
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Si-RNA duplexes was diluted in medium without serum and mixed gently. 
INTERFERinTM transfection reagent was added to the diluted si-RNA duplexes and 
the mixture was homogenized for 10 seconds immediately. The mixture was 
incubated for 10 minutes at room temperature to form transfection complexes 
between siRNA duplexes and INTERFERinTM. During complex formation, the 
growth medium was removed and fresh prewarmed complete medium was added to 
each well. The transfection mix was added onto the cells and then was homogenized 
by gently swirling the plate. The plate was incubated at 37°C. The medium was 
replaced with growth medium 6h after transfection. Cells were further incubated 
according to the experiment need. 
 
Table 1: Protocol for transfection in different plate formats. 
Culture 
 format 
Volume of 
si-RNA 
Volume of 
INTERFERin™ 
Volume of 
medium 
without serum 
for complexe 
formation 
Volume of 
complete 
medium on 
cells 
Final 
volume 
96-well 0.23 μl 1.5 μl 50 μl 125 μl 175 μl 
6-well 2.5μl 11 μl 200 μl 2 ml 2.2 ml 
60 mm 5 μl 22 μl 400 μl 4 ml 4.4 ml 
100 mm 12 μl 52.5 μl 500 μl 10 ml 10.5 ml 
8-well 
chamber 
slide 
0.46 μl 3 μl 100 μl 250 μl 350 μl 
 
3.2.3 RNA isolation from cultured cells 
Cells were rinsed with PBS, and then were lysed directly in the culture dish by 
addition of 1 ml TriFast (peqGOLD TriFast, Peqlab Biotechnology GmbH, Erlangen, 
Germany) to the dish and passing the cell lysate several times through a pipette. The 
amount of TriFast needed is based on the area of the culture dish (1 ml per 10 cm2) 
and not on the number of cells. Then cells were scraped in TriFast and the lysate was 
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transfered to an appropriate fresh tube. The samples were kept for 5 min at room 
temperature, then were shaken by hand vigorously after addition of 0.2 ml chloroform 
per 1 ml TriFast for 15 seconds. The samples were kept for 3-10 minutes at room 
temperature and then were centrifuged for 10 min at 12,000g (4°C). The mixture was 
separated into a lower red (phenol-chloroform) phase, an interphase and a colorless 
upper aqueous phase. RNA was forced exclusively into the aqueous phase and the 
aqueous phase was transferred to a fresh tube. To precipitate the RNA, 0.5 ml 
isopropanol per 1 ml of TriFast used for the initial homogenization was added to this 
tube. Then the tube was shaken and was incubated on ice for 15 min. After that, the 
tube was centrifuged for 10 min at 12,000g (4°C). The RNA pellet should form a gel 
like precipitate on the bottom side of the tube. The supernatant was removed carefully 
and the RNA pellet was washed twice with 75% ethanol by vortexing and subsequent 
centrifugation for 8 min at 7,500g (4°C). The excessive ethanol was removed from the 
RNA pellet by air-drying. Later the RNA pellet was resuspended in RNAse-free water. 
RNA was quantified by spectrophotometer (GeneQuant 1300, GE scientific, UK). 
 
3.2.4 Preparation of cDNA from RNA probes 
 
For the preparation of cDNA, 1 µg RNA per sample was used. RNA was copied to 
cDNA using reverse transcriptase (RevertAidTM Reverse Transcriptase) and 
random-hexamer primer (Fermentas). For the negative control, RevertAidTM Reverse 
Transcriptase was omitted and H2O (Aqua ad iniectabilia, Braun, Germany) was used 
instead. 
 
1 µg RNA in H2O (total volume 10.5 µl) including DNase I was heated up to 37°C for 
30 min, 75°C for 5 min, and then cooled down to 4°C. This step is to eliminate DNA. 
1µl random-hexamer primer was added to each RNA mixture and the mixture was 
denatured at 65°C for 5 min followed by rapid cooling and addition of 7.5 µl of the 
following master mixture: 
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5 x first strand buffer 4 µl 
40 mM dNTP mix (Fermentas) 2 µl 
RiboLock RNase Inhibitor 0.5 µl 
RevertAidTM Reverse Transcriptase 1 µl (omitted in negtive controll) 
H2O 1 µl (only used in negtive controll) 
 
The denatured RNA mixed with master solution was then subjected to cDNA 
synthesis by incubating at 25°C for 5 min, 42°C for 60 min followed by inactivation 
of enzymes at 70°C for 10 min. 
 
3.2.5 Real-time quantitative PCR (qPCR) 
 
The transcriptional regulation of selected genes was analyzed using real-time 
quantitative PCR (IQTM 5 Multicolor Real-time PCR detection system, BIO-RAD). 
Real-time PCR is a method based on the detection and quantification of a fluorescent 
reporter signal that increases in direct proportion to the amount of the PCR product in 
reaction (Livak et al., 1995), (Lee et al., 1993), using ABsoluteTM QPCR SYBR 
Green Mix (Thermo Fisher Scientific Inc, UK). CDNA was detected and quantified 
with the fluorescent dye SYBR Green, which offered a linear dose response over a 
wide range of target concentrations. As cDNA accumulates, the dye generates a signal 
that is proportional to the cDNA concentration. Fluorescein Dye acts as a passive 
reference dye to facilitate normalization of data. PCR reactions were performed in 25 
μl volume by using the qPCR mix. 
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qPCR mix Stock solution 
Quantities per 
reaction 
ABsoluteTM QPCR 
SYBR Green 
fluorescein Mix 
2x (Thermo-StartTM DNA 
Polymerase, Proprietary 
reaction buffer, dNTPs 
including dTTP, SYBR Green 
dye I, 3 mM MgCl2, 
Fluorescein Dye) 
12.5 μl 
Forward primer 10 pmol/μl 0.25 μl 
Reverse primer 10 pmol/μl 0.25 μl 
H2O  11 μl 
cDNA 
derived from 1µg 
RNA 
 1 μl 
 
Cycling conditions were as follows:  
cycle 1: 95°C for 15 min;  
cycle 2: 44 cycles of 95°C for 15 s, 55°C for 15 s and 72° C for 30 s;  
cycle 3: 95°C for 30 s, 60°C for 30 s;  
cycle 4: 71 cycles of 60°C for 10 s .  
Formation of a single specific PCR product was confirmed by melting curve analysis. 
β-actin served as a reference gene for all real-time PCR reactions. Relative changes in 
gene expression were determined with the ΔCt method using the following formula: 
ΔCt = (Ct reference – Ct target). (Livak and Schmittgen, 2001). 
 
3.2.6 Immunocytochemistry analysis 
 
The immunocytochemistry analysis was measured by Catalyzed Signal Amplification 
(CSA) System (Dako, Hamburg, Germany). 
 
On the first day, T24, UMUC-3 and EJ-28 cells were plated on 8-well glass chamber 
slides (Nalge Nunc International, Naperville, IL) at 6000/cm2, 12000/cm2 and 
5000/cm2, respectively. On the second day the cells were transfected with si-Random 
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or si-MAGE-A3 according to the transfection protocol. The cells were cultured for 72 
hours after transfection, and then the cells were measured by CSA system. The cells 
on slides were fixed in 4 % paraformaldehyde for 10 min, and then were washed in 
PBS. The slides were immersed in Target Retrieval Solution and were heated up to 90 
oC for 20 min. The slides were washed in TBST for 5 min. The slides were then 
incubated sequentially with hydrogen peroxide, Protein Block reagent, Primary 
antibody (Anti-human MAGE-A3, 1:50 dilution) (for negative control, the negative 
control reagent was used instead), Link Antibody, Streptavidin-Biotin Complex, 
Amplification Reagent, then Streptavidin-Peroxidase Reagent, and each incubation 
was followed by one wash with TBST. Substrate-Chromogen Solution was applied to 
cover specimen for 5 min at RT and the slides were rinsed gently with distilled water. 
The slides were immersed in hematoxylin, and then were rinsed gently with distilled 
water. The slides were then washed sequentially by dipping ten times each in: 70% 
ethanol, 100% ethanol, Xylenes. Specimen was mounted by glass coverslips using 
mounting medium. Images were acquired as JPEG format files with a Axiovert 200 
Inverted microscope (Carl Zeiss Light Microscopy, Göttingen, Germany). 
 
3.2.7 Cell count assay 
 
Cell proliferation was measured by cell count assay. This method is to count cells 
from distinct groups with different treatment. On the first day, T24, UMUC-3 and 
EJ-28 cells were plated on 60mm diameter dishes at 6000/cm2, 12000/cm2 and 
5000/cm2, respectively. Each cell line consisted of two dishes, as one dish for each 
si-RNA(si-Random, si-MAGE-A3). On the second day the cells were transfected with 
si-RNA according to the transfection protocol. The cells were cultured 72 hours after 
transfection. Then the cells from each respective dish were detached using trypsin and 
counted. 
 
3.2.8 Colony formation assay of cells in vitro 
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Colony formation assay is an in vitro microbiology technique for studying the 
effectiveness of specific agents on the survival and proliferation of cells based on the 
ability of a single cell to grow into a colony. The colony is defined to consist of at 
least 50 cells. The assay essentially tests every cell in the population for its ability to 
undergo ‘‘unlimited’’ division. 
 
For this assay three cell lines were characterized: T24, UMUC-3 and EJ-28. Two 
60mm diameter dishes were seeded from each cell line, with one dish for each 
si-RNA (si-Random, si-MAGE-A3). On the second day, the cells were transfected 
according to the transfection method. On the third day, they were trypsinized with 1 x 
trypsin for approximate 5 min at 37°C. The reaction was stopped by adding medium 
with 10% FCS containing trypsin inhibitors. For continuous culture three 60mm 
diameter dishes were established from each dish of these three cell lines at appropriate 
densities (T24 500cells/dish, UMUC-3 400cells/dish, EJ-28 300cells/dish). And then 
the cells were incubated for 14 days. After that , medium of the dishes was discarded 
and dishes were washed with 1x PBS, and then 2 ml of crystal violet stain (0.1% 
crystal violet, 10% formaldehyde, PBS) was added to each dish and incubated for 15 
min at RT. The crystal violet stain was discarded and dishes were washed by tap water. 
The dishes were left to dry in normal air at room temperature. Then the colonies were 
counted. 
 
3.2.9 2,3-Bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carbox-anilide 
(XTT) viability assay 
 
Cell viability was assessed by TACS® XTT kit (Trevigen Inc., Gaithersburg, USA). 
The use of tetrazolium salts, including XTT (2,3-Bis(2-methoxy-4-nitro-5- 
sulfophenyl)-2H-tetrazolium-5-carbox -anilide), to assay cell proliferation, cell 
viability, and/or cytotoxicity is a wide-spread, established practice. Cleavage of the 
tetrazolium salt to formazan occurs via the succinate-tetrazolium reductase system in 
the mitochondria of metabolically active cells. XTT, a yellow tetrazolium salt, is 
Materials and methods  
 
 
27 
cleaved to a soluble orange formazan dye, which can be measured by absorbance at 
490 (or 450) nm in a microplate reader. (* modified from the instruction of the kit) 
 
For this assay three cell lines were characterized: T24, UMUC-3 and EJ-28. One day 
before experiment, cells were seeded in a 96-well plate at varying densities (T24 
3300cells/well, UMUC-3 9000cells/well, EJ-28 3600cells/well) in 100 μl medium, 
with triplicate wells for each si-RNA (si-Random, si-MAGE-A3) of each cell line. On 
the second day, transfection of si-RNA was performed as described in transfection 
method. The plate was incubated for 72 h. On the fourth day, the plate was measured 
by XTT assay. To prepare XTT Working Solution, XTT reagent and activator were 
warmed to 37°C for several minutes. Immediately before use, 100 μl of the XTT 
activator was added to 5 ml of XTT reagent to make XTT Working Solution. 50μl of 
prepared XTT Working Solution was added to each well, and then the plate was 
incubated for 4 hours at 37°C under 5% CO2. The absorbance of samples at 490 nm 
was measured by spectrofluorometer (FL-600) (BioTek Instruments GmbH, Bad 
Friedrichshall, Germany). 
  
3.2.10 Measurement of cell apoptosis  
 
Cell apoptosis was measured by TumorTACS™ In Situ Apoptosis Detection kit 
(Trevigen, Gaithersburg, USA). This Kit is designed specifically for the detection of 
DNA fragmentation in cancer cells in culture. 
 
A common biochemical marker of apoptosis is DNA fragmentation. During apoptosis 
the chromosomal DNA is cleaved by endonucleases to generate DNA fragments with 
free 3'-hydroxyl residues. In situ, the 3' ends of cleaved DNA fragments provide a 
substrate for the enzyme terminal deoxynucleotidyl transferase (TdT) which adds 
nucleotides at the site of DNA breaks. The incorporation of biotinylated nucleotides 
allows chromosomal DNA fragmentation to be visualized by binding 
streptavidin-horseradish peroxidase followed by reaction with diaminobenzidine 
(DAB) to generate a dark brown precipitate (* modified from the instruction of the 
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kit). 
 
For this assay T24 cells were employed. On the first day, cells were seeded at 6000 
cells/cm2 in 400 μl of medium on an 8-well chamber slide. On the second day, 
transfection of si-RNA was performed as described in transfection method. The slide 
was incubated for 72 h. On the fifth day, the slide was measured by the apoptosis 
assay. The medium was removed and cells were rinsed once with 1X PBS at room 
temperature. The cells were incubated for 10 minutes at room temperature in 3.7% 
buffered formaldehyde. The slide was washed once in 1X PBS. After that, the 
samples were immersed in 1X PBS for 10 minutes and then were covered with 50 μl 
CytoninTM for 30 minutes. The slide was washed two times in deionized water. The 
samples were immersed in Quenching Solution for 5 minutes and then were washed 
in 1X PBS for 1 minute. Afterwards, the samples were immersed in 1X TdT Labeling 
Buffer for 5 minutes and then were incubated with 50 μl of Labeling Reaction Mix for 
60 minutes at 37 ˚C in a humidity chamber. The samples were then immersed in 1X 
TdT Stop Buffer for 5 minutes followed with one wash in 1X PBS. Then the samples 
were incubated with 50 μl of Strep-HRP Solution for 10 minutes at room temperature 
in a humidity chamber to avoid evaporation. The slide was washed two times in 1X 
PBS and then was immersed in DAB solution for 2 to 7 minutes. After that, the slide 
was washed 4 times in deionized H2O and was subsequently immersed in 1% Methyl 
Green for 30 seconds. The slide was dipped sequentially in deionized water, 95% 
ethanol, 100% ethanol, then xylene. Samples were mounted by glass coverslips using 
mounting medium. Images were acquired as JPEG format files with the Axiovert 200 
Inverted microscope. Cells containing fragmented nuclear chromatin characteristic of 
apoptosis will exhibit a brown nuclear staining that may be very dark after labeling, 
whereas cells without brown staining were defined as non-apoptotic cells. 
 
3.2.11 Expression analysis of the relative levels of cell cycle and apoptosis related 
proteins 
 
Analyzing the expression profiles of cell cycle and apoptosis related proteins is 
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helpful for understanding the roles these signaling molecules play in mechanisms 
related to programmed cell death and cell cycle. This assay was measured by 
Proteome ProfilerTM
 
Array Human Apoptosis Array Kit (R&D systems, Inc., 
Minneapolis, USA). The Human Apoptosis Array is a rapid and sensitive tool to 
simultaneously detect the relative levels of expression of 35 cell cycle and apoptotic 
proteins. 
 
For this assay T24 cells were employed. On the first day, cells were plated on 10cm 
diameter dishes at 6000 cells/cm2. On the second day, transfection of si-RNA was 
performed as described in transfection method. The dishes were incubated for 72 h. 
On the fifth day, the dishes were rinsed with PBS and were added with lysis buffer. 
The cells were resuspended by pipetting up and down and then were rocked gently at 
2-8 °C for 30 minutes. The cell lysates were centrifuged at 14,000 x g for 5 minutes, 
and then the supernatants were transfered into clean test tubes. 
Quantitation of sample protein concentrations was performed with Pierce BCA 
protein assay (Pierce, Rockford, USA). In this assay, a series of dilutions of known 
concentration of bovine serum albumin (BSA) and protein samples with 1:10 dilution 
by dest. H2O were prepared. Working solution was prepared by mixing 50 parts of 
BCA reagent A with 1 part of BCA reagent B (reagent A:B, 50:1). Then 200 µl 
working solution was added to each well after pipetting 25 µl of each standard or 
unknown sample replicate into a 96 well plate. After incubation of the plate at 37°C 
for 30 min, the absorbance of samples at 492 nm was measured by spectrofluorometer 
(FL-600) (BioTek Instruments GmbH, Bad Friedrichshall, Germany) and 
concentration of protein was determined based on the standard curve. 
We used 400 μg of each sample for the next steps. 2 ml of blocking buffer was 
pipetted into each well of a 4-well multi-dish. One array was placed into each well of 
the 4-well multi-dish and was incubated for 1 hour on a rocking platform shaker. 
While arrays were blocking, the samples were prepared by adding the desired quantity 
of lysate to 1.25 ml of the blocking buffer and then were adjusted to a final volume of 
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1.5 ml with Lysis Buffer as necessary. The buffer was removed from the multi-dish. 
Prepared samples were added into the multi-dish and the dish was incubated overnight 
at 2-8 °C on a rocking platform shaker. Each array was placed into individual plastic 
containers containing 20 ml of Wash Buffer. The arrays were washed with Wash 
Buffer for 10 minutes on a rocking platform shaker and this step was repeated two 
times for a total of three washes. For each array, 15 μl of reconstituted Detection 
Antibody Cocktail was diluted to 1.5 ml with Array Buffer. 1.5 ml of diluted 
Detection Antibody Cocktail was pipetted into each well of the multi-dish. Each array 
was returned to the multi-dish containing the diluted Detection Antibody Cocktail. 
The arrays were incubated for 1 hour on a rocking platform shaker. Each array was 
washed as described previously. The Streptavidin-HRP was diluted in Array Buffer 
and 2 ml of diluted Streptavidin-HRP was pipetted into each well of the 4-well 
multi-dish. Each membrane was returned to the 4-well multi-dish containing the 
diluted Streptavidin-HRP. After that, the arrays were incubated for 30 minutes on a 
rocking platform shaker and then were washed as described previously. Each 
membrane was placed on the bottom sheet of a plastic sheet protector with the 
identification number facing up. The arrays were detected by ECL (Enhanced 
Chemi-luminescence, Amersham, Germany) treatment, followed by exposure of the 
membrane in FluorChemTM 8900 chemi-luminescence imager (Alpha Innotech, 
California, USA). Quantitation of signal intensity was performed with the AlphaEase 
FC software (Alpha Innotech, California, USA). 
 
3.3 Statistical analysis 
 
All the data in the figures and text are expressed as means ± SEM of n independent 
observations unless indicated otherwise. Statistical evaluation was performed by 
paired t-test. 
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4. Results 
 
4.1 Expression studies of MAGE-A3 in a panel of different bladder cancer cell 
lines. 
 
At first, we analyzed the expression of MAGE-A3 in different bladder cancer cell 
lines. MAGE-A3 mRNA was analyzed by quantitative realtime RT-PCR in T24, 
HT-1376, BFTC-905, 5637, EJ-28, and UMUC-3 cells (Figure 3A). High levels of 
MAGE-A3 mRNA were observed in T24, UMUC-3 and 5637 cells, whereas no 
detectable levels were observed in EJ-28 cells. BFTC-905 and HT-1376 cells 
exhibited intermediate MAGE-A3 mRNA levels. Transfection of cells with a control 
siRNA(si-Random) had no effect on MAGE-A3-mRNA levels when compared to 
non-treated cells (Figure 3B). 
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Figure 3: The expression of MAGE-A3 in different bladder cancer cell lines 
A: Quantification of MAGE-A3 mRNA levels by real time RT-PCR of RNA extracts from 
T24, HT-1376, BFTC-905, 5637, EJ-28, and UMUC-3 cells. Different batches of cultured 
cells available in our laboratory were measured. The respective n-number is reflected by the 
number of symbols indicated 3<n<6) . β-actin mRNA was used as reference for Ct 
calculation. The highest MAGE-A3-mRNA concentrations are observed in UMUC-3 cells 
followed by T24 cells. In EJ-28 cells, MAGE-A3-mRNA was not detectable. Values are 
presented as mean, SEM, as well as single values (n.d., non-detectable). B: MAGE-A3 
mRNA analysis of RNA extracts from T24, UMUC-3 and EJ-28 cell lines. 
MAGE-A3-mRNA levels of naïve cells (control) were compared to cells that were transfected 
with control siRNA (si-Random). Values are presented as mean, SEM, n=3. No significant 
differences were obvious (paired t-test: p>0.05). 
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4.2 Establishment of selective silencing of MAGE-A3 by RNA interference 
(siRNA) 
 
For analyzing the biological function of MAGE-A3, knockdown (silencing) of 
MAGE-A3 expression by RNA interference was established. We transfected small 
interfering RNA (si-RNA) targeting MAGE-A3 (si-MAGE-A3) compared to a 
non-target control si-RNA (si-Random). The silencing effect was validated by real 
time RT-PCR analysis of mRNA extracts from the transfected cells. An approximate 
down-regulation of MAGE-A3 mRNA level by 80 % was observed in T24 and 
UMUC-3 cells transfected with si-MAGE-A3 when compared to si-Random treated 
cells, whereas no detectable MAGE-A3 levels were observed in non-MAGE-A3 
expressing EJ-28 cells (Figure 4A). Moreover, silencing of MAGE-A3 expression 
was supported at the protein level by immunocytochemistry analysis showing weaker 
cytoplasmic staining in T24 and UMUC-3 cells treated with si-MAGE-A3 when 
compared to si-Random treated cells. No obvious difference in staining could be 
observed between si-MAGE-A3 and si-Random groups in EJ-28 cells (Figure 4B). 
 
 
Results  
 
 
34 
 
A 
-20
-15
-10
-5
0
n.d.
si-Random
si-MAGE-A3
  T24                      UMUC-3                     EJ-28
**
*

C
t
M
A
G
E
-A
3
 /

-a
c
ti
n
 m
R
N
A
 
B 
 
 
Figure 4: Silencing of MAGE-A3 expression by si-RNA 
A: MAGE-A3 mRNA analysis by real time RT-PCR of RNA extracts from T24, UMUC-3 
and EJ-28 cells transfected with si-MAGE-A3 or si-Random (n.d.: non-detectable). Values are 
presented as mean, SEM, n=3. Significant differences, paired t-test: *p<0.05, **p<0.01. B: 
Immunocytochemistry of MAGE-A3. In the upper lane, non-treated control cells (control) 
without primary anti-MAGE-A3 antibody are displayed (-). In the lower two lanes, cells are 
shown that were transfected with si-Random or si-MAGE-A3. Here, the MAGE-A3 antibody 
was included (+). In the Si-Random lane, obvious immunostaining was observed in T24 and 
UMUC-3 cells (brown color) when compared to control group (without MAGE-A3-antibody). 
In si-MAGE-A3 treated T24 and UMUC-3 cells, the staining appears weaker. In comparison, 
immunostaining of EJ-28 cells without detectable MAGE-A3-mRNA appears less intensive 
(close to background level). 
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4.3 Effects of silencing of MAGE-A3 on cell proliferation and viability 
 
In order to analyze whether MAGE-A3 affects oncogenicity in bladder cancer cells, 
we performed assays regarding cell proliferation and viability after silencing of 
MAGE-A3. To follow this aim we employed the following three different methods. 
 
The first method used was cell count analysis. As shown in Figure 5, the cell numbers 
of T24 and UMUC-3 cell lines were both significantly increased when transfected 
with si-MAGE-A3 as compared to si-Random treated cells, whereas there was no 
significant difference between si-MAGE-A3 and si-Random groups in EJ-28 cells. 
 
 
 
Figure 5: Effect of silencing MAGE-A3 on cell proliferation by cell count assay 
Presented are the relative cell densities of si-Random group (normalized to 1) and the 
si-MAGE-A3 group. Values are presented as mean, SEM, n=3. Significant differences, paired 
t-test: *p<0.05. 
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The second method used was colony formation assay. As shown in Figure 6, 
suppression of MAGE-A3 by si-MAGE-A3 resulted in significant increases of colony 
number in T24 and UMUC-3 cells as compared to si-Random, whereas no significant 
difference was observed in EJ-28 cells. 
 
A                               B 
 
 
Figure 6: Effect of silencing MAGE-A3 on cell viability by colony formation assay 
A: Colony formation assay showing that silencing of MAGE-A3 resulted in significantly 
increased outgrowth of T24 and UMUC-3 cells, whereas there was no significant difference 
in EJ-28 cells. B: Quantitative analysis: a colony was defined to consist of at least 50 cells. 
The colony numbers were measured from T24, UMUC-3 and EJ-28 cells transfected with 
si-MAGE-A3 or si-Random. Values are presented as mean, SEM, n=3. Significant differences, 
paired t-test: *p<0.05). 
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The third method used was XTT assay, a viability assay which strongly correlates 
with cell proliferation. In accordance with the previous observations, this assay 
showed significant increases of viable cells in T24 and UMUC-3 cells transfected 
with si-MAGE-A3 when compared to si-Random, while no significant difference was 
observed in EJ-28 cells (Figure 7). 
 
 
Figure 7: Effect of silencing MAGE-A3 on cell proliferation (XTT assay) 
The relative values (si-Random group normalized to 1) are shown. Values are presented as 
mean, SEM, significant differences between si-MAGE-A3 and si-Random groups, n=6 (T24), 
n=9 (UMUC-3 and EJ-28), paired t-test: *p<0.05, ***p<0.001. 
 
4.4 Effect of silencing of MAGE-A3 on cell apoptosis 
 
Next, we analyzed potential effect of MAGE-A3 on apoptosis by Tunel assay based 
on DNA laddering in T24 cells. 
 
As depicted in Figure 8, this assay showed a decreased occurence of apoptosis in the 
si-MAGE-A3 group when compared with si-Random group. Since the incidence of 
apoptosis was observed at a low level below 1%, the biological significance of this 
finding remains unclear. 
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Figure 8: Apoptosis analysis after silencing of MAGE-A3 in T24 cells  
Microscopic analysis of cell apoptosis by in situ Tunel assay after silencing MAGE-A3 in 
T24 cells (▲ indicates apoptotic cells, △ indicates non-apoptotic cells. Bar scale represents 
50μm). 
Table 2 : Quantitative analysis of the Tunel assay. 
Silencing of MAGE-A3 resulted in decreased apoptotic incidence when compared to 
si-Random group. 
 
4.5 Expression analysis of the relative levels of cell cycle and apoptosis related 
proteins 
 
In order to analyze possible signal transduction pathways that are responsible for 
changes in cell proliferation and viability, we performed proteomic array analysis of 
T24 cells treated with si-MAGE-A3 compared to si-Random. We observed most 
striking differences in up-regulation of livin and down-regulation of cyclin-dependent 
kinase inhibitor p21 and differently phosphorylated p53 (tumor suppressor) forms. 
These changes may contribute to the enhanced survival and proliferation observed in 
the si-MAGE-A3 treated group (Figure 9). 
 
 
 
 
 
Table 2 : Quantitative analysis of the Tunel assay 
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Figure 9: Expression analysis of the relative levels of cell cycle and apoptosis related 
proteins 
A: Autoradiography of proteomic array of cell cycle and apoptotic proteins in T24 cells 
treated with si-Random or si-MAGE-A3. B: Quantitative analysis by densitometric scanning 
and normalization of protein signals from the autoradiography. Displayed is the fold-change 
of signal intensity in si-MAGE-A3 compared to si-Random treated group. All names of 
protein from the array are named. 
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5. Discussion 
 
So far, the expression of MAGE-A3 has mainly been studied in bladder cancer tissues 
(Dyrskjot et al., 2012; Sharma et al., 2006; Yin et al., 2011) whereas possible 
functions of MAGE-A3 in bladder cancer cell lines are largely unknown. Functional 
analyses about MAGE were performed in melanoma cells, myeloma cells, lung 
cancer cells, breast cancer cells, ovarian cancer cells, and others (Atanackovic et al., 
2010; Duan et al., 2003; Monte et al., 2006; Nardiello et al., 2011; Peikert et al., 2006; 
Xia et al., 2012; Yang et al., 2007). Against the background of these studies, we 
analyzed the expression and function of MAGE-A3 in a panel of human bladder 
cancer cell lines. 
 
According to our analysis of MAGE-A3 expression, we could demonstrate quite 
different expression patterns of MAGE-A3 mRNA in human bladder cancer cell lines 
including cells with relative high (T24, 5637 and UMUC-3 cells), intermediate 
(HT-1376, BFTC-905 cells) and nondetectable levels (EJ-28 cells). We selected two 
cell lines with high MAGE-A3 mRNA expression (T24, UMUC3) and one cell line 
with nondetectable MAGE-A3 mRNA expression (EJ-28) serving as control cells for 
the functional studies. 
 
It has to be mentioned that the selection of cells was mainly based on quantitative 
mRNA expression analysis of cell lines since subtype specific analysis of MAGE-A3 
at the protein level is difficult to perform due to the high conservation between 
MAGE-A family members (Figure 10). Thus, it is difficult to develop antibodies that 
can distinguish different MAGE proteins. Anti-MAGE antibodies may cross-react 
with other MAGE subtypes. For instance, the anti-MAGE-A3 antibody employed 
cross-reacts with MAGE-A1, -A4, -A6, and -A12 (Busam et al., 2000; Rimoldi et al., 
2000). Detection of MAGE-A3 at the mRNA level has the advantage to allow 
improved differentiation between different MAGE subtypes. Thus, studying 
MAGE-A3 expression at the protein level by immunocytochemistry may reflect the 
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sum of signals derived from different MAGE subtypes. 
 
 
Figure 10: Structural feature of the human MAGE-A family proteins (MAGEA1, -A2, 
-A3, -A4, -A5, -A6, -A8, -A9, -A10, -A11, -A12) except for MAGE-A7 (pseudogenes)  
MAGE NH2-terminal region (MAGE_N), MAGE homology domain (MHD) and MAGE 
COOH-terminal region (MAGE_C) are indicated. There are no predicted domains in 
MAGE_N and MAGE_C regions. 
*Figure modified from Sang M et al.(Sang et al., 2011a). 
 
We established an effective way for silencing of MAGE-A3 by siRNA for 
investigating the biological function of MAGE-A3 in bladder cancer cells. Based on 
in silico screening, we could identify one siRNA motif that potently inhibited the 
expression of MAGE-A3 in T24 and UMUC-3 cells. Employing this siRNA sequence 
we performed the functional experiments. 
 
These experiments included analyses of cell proliferation, colony formation and 
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apoptosis. We observed inhibition of cell proliferation and survival mediated by 
MAGE-A3 whereas apoptosis was increased. 
 
For identifying possible signal transduction pathways affected by MAGE-A3, 
proteomic array analysis of proteins regulating cell cycle and apoptosis was 
performed. We found most striking differences in up-regulation of livin and 
down-regulation of p21 and differently phosphorylated p53 forms after silencing of 
MAGE-A3. 
 
Interestingly, our results suggested that MAGE-A3 might play an important role in 
inhibition of survival of bladder cancer cells and it might have an anti-oncogenic 
function. In contrast, MAGE-A3 subtype has been mainly attributed to exert 
pro-proliferative and anti-apoptotic characteristics. Djordje Atanackovic et al. 
(Atanackovic et al., 2010) demonstrated that MAGE-A3 promoted the survival of 
multiple myeloma cells by suppressing apoptosis. It was reported that 
down-regulation of type I MAGE proteins including MAGE-A3 led to p53 
transcriptional induction and p53-dependent apoptosis in melanoma and myeloma 
cells (Nardiello et al., 2011; Yang et al., 2007). It was also shown that inhibition of 
MAGE-A3, which resulted in p53 and p21 accumulation, could reduce the 
proliferation of pituitary cells (Zhu et al., 2008). These studies displayed effects of 
MAGE-A3 on cell survival and apoptosis. In our study, we identified livin, p21 and 
phosphorylated p53 forms as important targets that were markedly altered by 
MAGE-A3 as revealed by proteomic array approach and it demonstrated increased 
level of livin and decreased levels of p21 and phospho-p53 forms after silencing of 
MAGE-A3. Livin is considered as a member of the inhibitors of apoptosis family, and 
it promotes cell growth and inhibits apoptosis (Wang et al., 2010; Yang et al., 2010). 
p21 is a cyclin-dependent kinase inhibitor encoded by the CDKN1A gene in humans 
and functions as a regulator of cell cycle progression at G1 (el-Deiry et al., 1993; 
Harper et al., 1993; Li et al., 2011). p53 is a tumor suppressor protein encoded by the 
TP53 gene in humans and functions as a tumor suppressor that is related to preventing 
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cancer (Brosh and Rotter, 2010; Kern et al., 1991; Matlashewski et al., 1984; Paolella 
et al., 2011). Therefore, MAGE-A3 may inhibit survival and induce apoptosis of 
bladder cancer cells through inhibiting the expression of livin and augmenting the 
expression of p21 and phospho-p53 forms. 
 
Thus, our results suggest that MAGE-A3 does not only represent a tumor antigen but 
may inhibit cell survival and induce apoptosis. Surprisingly, these functions observed 
in bladder cancer cells are anti-oncogenic. They should be confirmed by further 
studies employing additional siRNA motifs. In our group, we tested several of them, 
however only one of them was functional operative. Furthermore, it is still unclear 
how livin, p21 and p53 are affected by MAGE-A3 at the molecular level. Direct or 
secondary interactions may be involved in this regard. 
 
One further important aspect to clarify remains the question why MAGE-A3 has 
opposite functions in different cancer cell lines. So far, the relevant mechanisms are 
not clear. Differences in cell type specific components that interact with MAGE-A3 
and that affect cell proliferation and apoptosis in a different way may be responsible. 
So far, only MAGE-A4 subtype has been linked to anti-oncogenic function as 
revealed by its pro-apoptotic characteristic in lung cancer cells. In this study, 
pro-apoptotic effects of MAGE-A4 could be attributed to enhanced caspase 3 
cleavage (Peikert et al., 2006). The functional accordance of MAGE-A4 in lung 
cancer cells and MAGE-A3 in bladder cancer cell lines may be related to the strong 
structural homology between MAGE-A3 and MAGE-A4 (Figure 10). 
 
At present, clinic trials of MAGE-A3 vaccination protocols are tested in bladder 
cancer. This treatment may initiate a cytotoxic immunresponse against tumor cells 
bearing MAGE-A3 antigens. In this approach, MAGE-A3 is targeted as a tumor 
selective antigen without considering any functional aspects of MAGE-A3. Based on 
our findings that MAGE-A3 may exert some anti-oncogenic function regarding 
proliferation and apoptosis, it would be of interest to analyse that to which extent 
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immunologic therapy targeting MAGE-A3 might affect anti-oncogenic function in 
bladder cancer cells.  
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6. Summary 
 
6.1 Summary 
 
MAGE-A3 is a member of the type I Melanoma Antigen Gene family and is 
expressed in various cancers including bladder cancer. MAGE-A3 represents a 
candidate antigen as a possible target for cancer immunotherapy. In particular, 
MAGE-A3 vaccination protocols are investigated in clinical trials in bladder cancer. 
So far, functional studies on MAGE were mainly performed in melanoma cells, 
myeloma cells, lung cancer and breast cancer cells whereas the function of 
MAGE-A3 in bladder cancer cells is largely unknown. 
 
Here, we analyzed the expression of MAGE-A3 in a panel of human bladder cancer 
cell lines and selected appropriate cells for functional studies. Furthermore, we 
established potent knockdown of MAGE-A3 by RNA interference and harnessed this 
technique for functional analysis of MAGE-A3. MAGE-A3 mRNA levels where 
highest in UMUC-3, 5637 and T24 cells whereas no detectable levels were observed 
in EJ-28 cells. BFTC-905 and HT-1376 cells exhibited intermediate MAGE-A3 
mRNA levels. For further experiments, T24, UMUC-3 and EJ-28 cells were selected 
and MAGE-A3 expression was confirmed at protein level by immunocytochemistry. 
Potent siRNA knockdown of MAGE-A3 mRNA was validated by RT-PCR exhibiting 
down-regulation of MAGE-A3 mRNA by approximately 80 % in T24 and UMUC-3 
cells. Evidence of MAGE-A3 knockdown could also be confirmed in a 
non-quantitative way by immunocytochemistry. EJ-28 cells that displayed no 
detectable MAGE-A3 mRNA abundance were included in these experiments as 
control cells. 
 
At the functional level, silencing of MAGE-A3 resulted in significant increased 
proliferation, cell count and colony formation in T24 und UMUC-3 cells, whereas 
EJ-28 cells were unaffected. Apoptosis was reduced after silencing of MAGE-A3 in 
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T24 cells. In order to get some mechanistic clue for this observation, proteomic array 
analysis of cell cycle regulatory and apoptotic proteins was performed in T24 cells 
demonstrating increased level of livin and decreased levels of cyclin-dependent kinase 
inhibitor p21 and tumor suppressor protein phospho-p53 forms after silencing of 
MAGE-A3. Thus, at the functional level we could demonstrate anti-proliferative and 
pro-apoptotic effects of MAGE-A3 indicating an anti-oncogenic characteristic. The 
anti-proliferative and pro-apoptotic effects of MAGE-A3 were accompanied by 
down-regulation of livin and up-regulation of p21 and phospho-p53 forms likely 
contributing to or mediating the observed effects. 
 
In sum, we selected suitable bladder cancer cell lines for analysis of MAGE-A3 and 
established efficient silencing of MAGE-A3. Interestingly, we revealed an important 
so far non-described anti-oncogenic function of MAGE-A3 in bladder cancer cells. 
This aspect should be considered when employing immunotherapeutic strategies 
targeting MAGE-A3 tumor antigen by antibodies. 
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6.2 Zusammenfassung 
 
MAGE-A3 ist ein Mitglied der Typ I Melanom Antigen Familie und kommt in 
verschiedenen Krebsarten, darunter auch Blasenkrebs, vor. MAGE-A3 repräsentiert 
ein mögliches Antigen für eine gezielte Krebs-Immunotherapie. So werden momentan 
MAGE-A3 Impfprotokolle für Blasenkrebs in klinischen Studien untersucht. Bisher 
erfolgten funktionelle Studien zu MAGE in Melanom-, Myelom-, Lungenkrebs- und 
Brustkrebszellen, während die Funktion von MAGE-A3 in Blasenkrebszellen unklar 
ist. 
 
In dieser Arbeit haben wir die Expression von MAGE-A3 in mehreren humanen 
Blasenkrebs-Zelllinien analysiert und geeignete Zellen für weitergehende Studien 
selektiert. Des Weiteren konnten wir eine stabile Suppression von MAGE-A3 durch 
RNA-Interferenz etablieren und diese Technik zur Funktionsanalyse von MAGE-A3 
ausnutzen. MAGE-A3 mRNA Konzentrationen waren am höchsten in UMUC-3, 5637 
und T24-Zellen, während in EJ-28 Zellen keine mRNA für MAGE-A3 detektierbar 
war. BFTC-905 und HT-1376 Zellen wiesen intermediäre MAGE-A3 
mRNA-Konzentrationen auf. In weiteren Experimenten wurde die MAGE-A3 
Expression an T24, UMUC-3 und EJ-28 Zellen auf Proteinebene mittels 
Immunzytochemie überprüft. Dabei zeigte sich deutliche MAGE-A3 
Immunreaktivität an T24 und UMUC Zellen, die an EJ-28 Zellen weniger ausgeprägt 
auf Hintergrundsniveau erschien. Effektive Suppression von MAGE-A3 mRNA durch 
RNA-Interferenz wurde durch quantitative RT-PCR validiert, welche eine Inhibition 
um ca. 80% zeigte, die durch Immunzytochemie bestätigt wurde. 
 
Auf funktioneller Ebene resultierte die Suppression von MAGE-A3 in signifikant 
erhöhter Proliferation, Zellzählung und Koloniebildung in T24 und UMUC-3 Zellen, 
während in EJ-28 Zellen keine Änderung zu beobachten war. T24 Zellen reagierten 
auf die Suppression von MAGE-A3 mit reduzierter Apoptose. Um diese 
Beobachtungen auf Signaltransduktionsebene fassen zu können, wurde an T24-Zellen 
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ein Proteom-Array von Zellzyklus und Apoptose regulierenden Komponenten 
durchgeführt. Hierbei zeigten sich bei den Zellen mit Suppression von MAGE-A3 
verminderte Spiegel von Cyclin-abhängigem Kinaseinhibitor p21- und 
phosphorylierten p53- Tumorsuppressor Protein und ein erhöhter Spiegel von Livin, 
die das gesteigerte Überleben der Zellen erklären könnten. 
 
Zusammenfassend haben wir geeignete Blasenkrebs-Zelllinien für die Analyse von 
MAGE-A3 identifiziert und an diesen Zellen eine effiziente Suppression von 
MAGE-A3 etabliert. Interessanterweise konnten wir eine bislang noch nicht 
beschriebene anti-onkogene Funktion von MAGE-A3 an diesen Zellen beobachten. 
Dieser Aspekt sollte bei der Entwicklung neuer Immunotherapieverfahren mit 
MAGE-A3 als Zielantigen berücksichtigt werde und entsprechende Effekte, die durch 
MAGE-A3 Antikörper ausgelöst werden, auf Tumorzellebene untersucht werden. 
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